Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. control; There are no OCU410-related serious adverse events reported across the Pha ...
CMS Suspends Automatic Denial of Institutional Claims Reporting Modifier -GA CMS has announced that Medicare contractors processing institutional claims should no longer automatically deny line items ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results